HYBRID EVENT: You can participate in person at Orlando, USA or Virtually from your home or work.

6th Edition of International Conference on Neurology and Brain Disorders

October 24 -26, 2022

October 24 -26, 2022 | Orlando, Florida, USA
INBC 2022

Ulrich Sprick

Speaker at Neurology and Brain Disorders 2022 - Ulrich Sprick
Alexius/Josef Clinic, Neuss, Germany
Title : MRI-navigated transcranial pulse stimulation (TPS) as an alternative option for severe treatment-resistant depression– a case report


Patients with severe therapy-resistant depressive disorders repeatedly pose enormous treatment challenges in psychiatry and neurology. Transcranial pulse stimulation (TPS) as a new non-invasive therapy method could represent a new alternative to standard treatment such as ECT, magnetic stimulation or deep brain stimulation. In contrast to ultrasound stimulation (tFUS) TPS uses shock waves. These shock waves allow an application to superficial brain structures as well as into deep brain areas without the induction of any thermal side effects. The stimulation of the target areas is MRI-guided with a similar precision as in a stereotactic procedure.

TPS is currently approved for the treatment of Alzheimer's disease. Since AD patients repeatedly reported significant improvements of their mood, a healing attempt was carried out in a patient with a severe therapy-resistant depression. An 81-year-old inpatient suffered from a major depressive disorder (lasting for longer than 18 months). All pharmacological approaches with different antidepressants (including ketamine) also in combination treatment and adjuvant therapy did not improve the status of the patient. ECT also did not lead to any positive change. The TPS-treatment was performed as a healing attempt. The patient received bilateral stimulation of the nucleus accumbens (the “reward center” of the brain) and the frontodorsal cortex (bilaterally 3,000 pulses per session, 0.2 mJ/mm2 per pulse, frequency 4 Hz). The navigated stimulation was carried out over a period of 2 weeks (with 3 sessions per week) by a Neurolith  apparatus (Storz Medical, Switzerland). In addition to the clinical assessment of depressive symptoms, standard tests with a TFDD and CERAD were carried out. The patient was examined and tested before TPS stimulation as well as 2 and 6 weeks later. A dementia syndrome was not present in the patient.

TPS stimulation led to an exceptional significant improvement in mood, which was also reflected in the TFDD (18/20 to 6/20). This improvement persisted for over 6 weeks. Side effects were not reported by the patient. This case shows that MRI-navigated TPS can be considered as an alternative method for therapy-resistant major depression. To determine the exact mechanisms of action of TPS further investigation is needed. In a rodent model it could be shown that TPS induced an increase of nitric oxide (NO)-levels. Both, the release of trophic factors and a temporarily opened blood-brain-barrier (BBB), seem to play a critical role. Thus a transient opening of the BBB might help to potentiate effects of administered pharmaceuticals contributing to an improvement of brain function.

In summary TPS is a very promising option as an adjunctive therapy to a state-of-the-art treatment which may achieve a reduction of depressive symptoms as well as an improvement of cognitive functions and  quality of life.

What will the audience learn from your presentation?
3 specific items:

  • Presentation of a new effective method of non-invasive brain stimulation with very low side effects
  • Beside the case report of a patient with a severe depression data of own treatments of Alzheimer’s Disease with TPS will be included
  • Discussion of the working mechanism of TPS


Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. Ulrich Sprick studied Medicine and Psychology at the University of Düsseldorf. He is an associated professor at the Medical Faculty of the University of Düsseldorf. Trained as a specialized psychiatrist and an expert psychologist in neuropsychology he works as Deputy Medical Director and Head of the Department of Dayclinics and Out-Patients of the Alexius/Josef Clinic in Neuss (Germany). He has been working in brain research for more than 20 years with special interests in brain stimulation, neuoplasticity, trophic factors, endogenous opiates and memory. From the clinical perspective his actual research interests include treatment of Alzheimer’s Disease and depression, nonvisual effects of light and telemedicine